; (C) accepting public comment on such proposed list and reasons for a period of not less than 60 days; (D) taking such comments into account in determining the final list under paragraph (1); and (E) addressing such comments in reporting under paragraph (3). (7) Additional considerations In developing and updating the list under paragraph (1), the Secretary shall consider— (A) the most recent annual threat-based review conducted by the Secretary under section 319F–2(a)(2), the most recent report of the Comptroller General of the United States under section 319F–2(a)(5), and the most recent recommendations of the Public Health Emergency Countermeasures Enterprise established under section 2811–1; (B) input from each member of the Public Health Emergency Countermeasures Enterprise (or a designee thereof); and (C) if available, the report of the National Academies of Sciences, Engineering, and Medicine prepared pursuant to section 3101 of the Coronavirus Aid, Relief, and Economic Stability Act ( Public Law 116–136 ). (b) Designation of critical medications for which availability is at risk in the event of a public health emergency (1) In general The Secretary shall— (A) evaluate each critical medication to determine whether there is adequate assurance that it will be available in sufficient quantities in the event of a public health emergency, on a timely basis, within each portion of the United States where it is needed; and (B) designate each critical medication with respect to which the Secretary determines there is not such an adequate assurance. (2) Factors to be taken into account In carrying out paragraph (1), the Secretary shall take into account factors including— (A) volume inventories of each critical medication that are normally available for use in the United States, in the public and private sector, in the absence of a public health emergency